RMR Wealth Builders acquired a new position in GALAPAGOS NV/S (NASDAQ:GLPG) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 396 shares of the biotechnology company’s stock, valued at approximately $78,000.

A number of other hedge funds have also bought and sold shares of the business. Cormorant Asset Management LP increased its position in shares of GALAPAGOS NV/S by 0.5% during the 2nd quarter. Cormorant Asset Management LP now owns 99,075 shares of the biotechnology company’s stock valued at $19,484,000 after purchasing an additional 472 shares during the last quarter. Capital Asset Advisory Services LLC boosted its holdings in shares of GALAPAGOS NV/S by 14.0% in the 2nd quarter. Capital Asset Advisory Services LLC now owns 1,994 shares of the biotechnology company’s stock worth $370,000 after buying an additional 245 shares during the last quarter. Stifel Financial Corp grew its position in GALAPAGOS NV/S by 2.9% during the second quarter. Stifel Financial Corp now owns 23,790 shares of the biotechnology company’s stock valued at $4,693,000 after buying an additional 664 shares during the period. Baird Financial Group Inc. increased its holdings in GALAPAGOS NV/S by 15.1% during the second quarter. Baird Financial Group Inc. now owns 2,020 shares of the biotechnology company’s stock worth $418,000 after buying an additional 265 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in GALAPAGOS NV/S by 1.1% in the second quarter. Federated Hermes Inc. now owns 1,421,640 shares of the biotechnology company’s stock worth $280,475,000 after acquiring an additional 15,097 shares during the period. 11.58% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently weighed in on GLPG. BidaskClub downgraded shares of GALAPAGOS NV/S from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 9th. Morgan Stanley reduced their price objective on GALAPAGOS NV/S from $221.00 to $158.00 and set an “equal weight” rating for the company in a report on Friday, August 21st. Barclays lowered GALAPAGOS NV/S from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, August 19th. HC Wainwright cut GALAPAGOS NV/S from a “buy” rating to a “neutral” rating and dropped their price target for the company from $270.00 to $123.00 in a research report on Monday, August 24th. Finally, Stifel Nicolaus reissued a “hold” rating on shares of GALAPAGOS NV/S in a report on Friday, September 11th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $190.23.

Shares of GLPG traded up $2.03 during midday trading on Wednesday, hitting $137.64. 2,239 shares of the company traded hands, compared to its average volume of 156,656. GALAPAGOS NV/S has a one year low of $112.00 and a one year high of $274.03. The firm has a market cap of $8.85 billion, a P/E ratio of 86.93 and a beta of 0.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.09 and a quick ratio of 9.09. The stock has a 50-day moving average of $158.81 and a 200-day moving average of $190.58.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.95) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.88). The firm had revenue of $129.53 million for the quarter, compared to analysts’ expectations of $118.41 million. GALAPAGOS NV/S had a net margin of 8.13% and a return on equity of 8.24%. Sell-side analysts forecast that GALAPAGOS NV/S will post -4.87 EPS for the current fiscal year.

GALAPAGOS NV/S Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: Percentage Decliners

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.